Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Dec;33(12):1631-5.

[Treating influenza patients of wind-heat affecting Fei syndrome by jinhua qinggan granule: a double-blinded randomized control trial].

[Article in Chinese]

Author information

  • 1Respiratory Department, Guang'anmen Hospital Affiliated to China Academy of Chinese Medical Sciences, Beijing 100053, China.
  • 2Emergency Department, Dongzhimen Hospital Affiliated to Bejing University of Chinese Medicine, Beijing 100700, China.
  • 3Respiratory Department, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100078, China.
  • 4Respiratory Department, Xiyuan Hospital Affiliated to China Academy of Chinese Medical Sciences, Beijing 100091, China.
  • 5Respiratory Department, Beijing Chinese Medicine Hospital Affiliated to Capital Medical University, Beijing 100010, China.
  • 6Respiratory Department, First Hospital Affiliated to Tianjin University of Tradi tional Chinese Medicine, Tianjin 300193, China.
  • 7Respiratory Department, Second Hospital Affiliated to Tianjin University of Traditional Chinese Medicine, Tianjin 300151, China.
  • 8Beijing Supertrack Medical Technology Development Co., Ltd., Beijing 100029, China.
  • 9Clinical Medicine Research Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Abstract

OBJECTIVE:

To assess the effect and safety of Jinhua Qinggan Granule (JHG) in treating influenza patients of wind-heat affecting Fei syndrome (WHAFS).

METHODS:

Totally 136 influenza patients of WHAFS were randomized by stratification into 3 groups, the high dose JHG group (44 cases, 10 g each time), the low dose JHG group (45 cases, 5 g JHG + 5 g placebo each time), and the placebo control group (47 cases, 10 g placebo each time). All medication was administered three times daily for 5 days. The fever disappearance time, the fever disappearance rate, efficacy of TCM syndrome, the disappearance rate of main symptoms and physical signs of flu, the negative rate of virus nucleic acid in the pharyngeal secretion, and safety indicators were assessed.

RESULTS:

The median fever disappearance time was 32.8 h (95% CI: 22.5-41.0 h) in the high dose JHG group, 26.0 h (95% CI: 14.5-36.5 h) in the low dose JHG group, 39.5 h (95% CI: 29.0-46.0 h) in the placebo control group. There was statistical difference in the median fever disappearance time between the low dose JHG group and the placebo control group (P = 0.011). Three days after treatment, the markedly effective rate of TCM symptoms in the low dose JHG group was 66.7%, higher than that of the placebo control group (38.3%), and its effective rate was superior to that of the high dose JHG group (P = 0.043). Five days after treatment, the recovery rate of the low dose JHG group (42.2%) was higher than that of the high dose JHG group (25.0%, P = 0.026) and that of the placebo control group (14.9%, P = 0.002). The markedly effective rate of the low dose JHG group (86.7%) was higher than that of the placebo control group (55.3%, P = 0.001). Similar effects were obtained in the low dose JHG group and the high dose JHG group, but slightly poor in partial indicators of the high dose JHG group. There was no statistical difference in adverse reaction among these three groups (P > 0.05).

CONCLUSIONS:

JHG was effective and safe in treating influenza patients of WHAFS. Routinely low dose was the optimal dosage of JHG.

PMID:
24517059
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk